FDA Grants Approval for Nintedanib Esylate ANDA219926 by Macleods Pharmaceuticals
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219926 for Nintedanib Esylate submitted by Macleods Pharmaceuticals.
Company
Macleods Pharmaceuticals
Asset
Nintedanib
Indication
Oncology / Small Molecule
Status
Approved
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The FDA's approval of Macleods Pharmaceuticals' generic Nintedanib Esylate introduces significant competition in the oncology market. This could impact pricing and market share for existing branded therapies, necessitating strategic adjustments from competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies of Macleods Pharmaceuticals following this approval.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.